+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030

  • PDF Icon

    Report

  • 150 Pages
  • January 2024
  • Region: Global
  • Lucintel
  • ID: 5928846

ACE Inhibitors Trends and Forecast

The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets. The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

ACE Inhibitors by Segment

The study includes a forecast for the global ACE Inhibitors by drug type, application, end use, and region.

ACE Inhibitors Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]

  • Lisinopril
  • Ramipril
  • Captopril
  • Moexipril
  • Fosinopril
  • Perindopril
  • Others

ACE Inhibitors Market by Application [Shipment Analysis by Value from 2018 to 2030]

  • Heart Failure
  • Hypertension
  • Chronic Kidney Disease
  • Diabetes
  • Others

ACE Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]

  • Hospitals
  • Pharmacies
  • Online Drug Stores
  • Others

ACE Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of ACE Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ACE Inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ACE Inhibitors companies profiled in this report include-
  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

ACE Inhibitors Market Insights

The publisher forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Features of the Global ACE Inhibitors Market

  • Market Size Estimates: Ace inhibitors market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Ace inhibitors market size by drug type, application, end use, and region in terms of value ($B).
  • Regional Analysis: Ace inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different drug type, application, end use, and regions for the ACE Inhibitors market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ACE Inhibitors market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the ACE Inhibitors market size?
Answer: The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030.

Q2. What is the growth forecast for ACE Inhibitors market?
Answer: The global ACE Inhibitors market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the ACE Inhibitors market?
Answer: The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

Q4. What are the major segments for ACE Inhibitors market?
Answer: The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets.

Q5. Who are the key ACE Inhibitors market companies?
Answer: Some of the key ACE Inhibitors companies are as follows:
  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company
Q6. Which ACE Inhibitors market segment will be the largest in future?
Answer: The publisher forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

Q7. In ACE Inhibitors market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Q.8 Do we receive customization in this report?
Answer: Yes,the publisher provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the ACE Inhibitors market by drug type (lisinopril, ramipril, captopril, moexipril, fosinopril, perindopril, and others), application (heart failure, hypertension, chronic kidney disease, diabetes, and others), end use (hospitals, pharmacies, online drug stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Global ACE Inhibitors Market: Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global ACE Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global ACE Inhibitors Market by Drug Type
3.3.1: Lisinopril
3.3.2: Ramipril
3.3.3: Captopril
3.3.4: Moexipril
3.3.5: Fosinopril
3.3.6: Perindopril
3.3.7: Others
3.4: Global ACE Inhibitors Market by Application
3.4.1: Heart Failure
3.4.2: Hypertension
3.4.3: Chronic Kidney Disease
3.4.4: Diabetes
3.4.5: Others
3.5: Global ACE Inhibitors Market by End Use
3.5.1: Hospitals
3.5.2: Pharmacies
3.5.3: Online Drug Stores
3.5.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global ACE Inhibitors Market by Region
4.2: North American ACE Inhibitors Market
4.2.1: North American ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
4.3: European ACE Inhibitors Market
4.3.1: European ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
4.3.2: European ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
4.4: APAC ACE Inhibitors Market
4.4.1: APAC ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
4.4.2: APAC ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
4.5: ROW ACE Inhibitors Market
4.5.1: ROW ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
4.5.2: ROW ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global ACE Inhibitors Market by Drug Type
6.1.2: Growth Opportunities for the Global ACE Inhibitors Market by Application
6.1.3: Growth Opportunities for the Global ACE Inhibitors Market by End Use
6.1.4: Growth Opportunities for the Global ACE Inhibitors Market by Region
6.2: Emerging Trends in the Global ACE Inhibitors Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global ACE Inhibitors Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global ACE Inhibitors Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: AstraZeneca
7.2: Abbott
7.3: Bausch Health Companies
7.4: Pfizer
7.5: AbbVie
7.6: Merck
7.7: Novartis
7.8: Johnson & Johnson
7.9: Sanofi
7.10: Eli Lilly and Company

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...